Getinge 2022 Annual Report

Getinge 2022 Annual Report Introduction Strategy Corporate Governance Annual Report Sustainability Report Other information Contents Surgical Workflows is a world- leading supplier of products and solutions that optimizes quality, safety and capacity usage of sterile supply departments and operating rooms. The offering includes: • • Solutions for sterile reprocessing of surgical instruments and endoscopes Equipment and design for surgical workplaces Digital healthcare solutions and software 09:20 • such as connected equipment 15 . • Service and project management ry Surgical Workflows Customers' needs Healthcare's access to effective infrastructure is of major impor- tance for surgical interventions to ensure a high level of clinical safety and quality. There is also a significant need to reduce the risk of healthcare-acquired infections, which entail additional suffering for patients, consume large amounts of resources and negatively impact society in general. Healthcare also needs to increase productivity to enable higher treatment volumes with limited resources. Research and development In Surgical Workflows, about 300 people work with R&D and the innovation pipelines have improved in the past few years. Beyond continuous innovation into legacy and new segments such as low-temperature sterilization and endoscopy reprocessing, the prioritized areas for R&D are connectivity and digital solutions, infection control consumables, value segments and logistic automation in the CSSD. The R&D activities also focus on scaling up recently completed acquisitions with new products such as biological indicators, fluorescence imaging and chemicals for sterile goods handling. There are also a couple of strategic innovation partnerships in the field of hybrid OR with key imaging players, and robotic surgery. Production sites Surgical Workflows has production sites in Sweden, Germany, France, UK, Poland, China and the US. The production site in Rastatt, Germany, was converted to processing climate-neutral gas in 2022, thereby contributing to the overall target of becoming carbon neutral by 2025. The business area has also invested in solar panels in Rastatt and in Suzhou, China, and in a geothermal heating system in Ardon, France. Sales and profitability Organic sales increased during the year after a period of subdued growth in 2020-2021, when hospitals focused on handling needs related to COVID-19. The increased sales and continued productivity improvements contributed to the operating margin strengthening year-on-year. 25 25

View entire presentation